Catalyst Wire Dossier Catalyst Wire Dossier

CHF5993 pMDI 100/6/12.5 µg HFA-152a

CHF5993 · Chiesi Farmaceutici S.p.A.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CHF5993 pMDI 100/6/12.5 µg HFA-152a, covering 2026-01-12 to 2026-01-12. Get the full timeline:

Most recent: Clinical Trial Update: Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma [Phase 2]

See pricing